Evidence map›Paper›PMID 30157197›Full record

ArticlePloS one2018

Predicting death and lost to follow-up among adults initiating antiretroviral therapy in resource-limited settings: Derivation and external validation of a risk score in Haiti.

Margaret L McNairy, Deanna Jannat-Khah, Jean W Pape, Adias Marcelin, Patrice Joseph, Jean Edward Mathon, Serena Koenig, Martin Wells, Daniel W Fitzgerald, Arthur Evans

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Margaret L McNairyDivision of General Internal Medicine, Weill Cornell Medicine, New York, United States of America.ORCID 0000-0001-7853-633X
Deanna Jannat-KhahDivision of General Internal Medicine, Weill Cornell Medicine, New York, United States of America.ORCID 0000-0002-1091-379X
Jean W PapeHaitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port au Prince Haiti.
Adias MarcelinHaitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port au Prince Haiti.
Patrice JosephHaitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port au Prince Haiti.
Jean Edward MathonHaitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port au Prince Haiti.
Serena KoenigDivision of Global Health Equity, Brigham and Women's Hospital, Harvard Medical School, Boston MA, United States of America.
Martin WellsDepartment of Statistical Science, Cornell University, Ithaca, United States of America.ORCID 0000-0002-9750-9529
Daniel W FitzgeraldCenter for Global Health, Weill Cornell Medicine, New York, United States of America.
Arthur EvansDivision of General Internal Medicine, Weill Cornell Medicine, New York, United States of America.ORCID 0000-0002-3077-116X
Cornell University · USGheskio Centers · HTBrigham and Women's Hospital · US

Funding

Training in pharmacokinetic and pharmacodynamics research in HIV and tuberculosisD43TW010062 · FIC · WEILL MEDICAL COLL OF CORNELL UNIV · PI FITZGERALD, DANIEL W · 2015 to 2019
$1.8M
Global Health Research Training in HIV and TuberculosisK24AI098627 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI FITZGERALD, DANIEL W · 2012 to 2022
$1.8M
FIC NIH HHS D43 TW010062NIAID NIH HHS K24 AI098627
6 · The paper itself

Abstract

backgroundOver 18 million adults have initiated life-saving antiretroviral therapy (ART) in resource-poor settings; however, mortality and lost-to-follow-up rates continue to be high among patients in their first year after treatment start. Clinical decision tools are needed to identify patients at high risk for poor outcomes in order to provide individualized risk assessment and intervention. This study aimed to develop and externally validate risk prediction tools that estimate the probability of dying or of being lost to follow-up (LTF) during the year after starting ART.

methodsWe used a derivation cohort of 7,031 adults age 15-70 years initiating ART from 2007 to 2013 at 6 clinics in Haiti; 242 (3.5%) had documented death and 1,521 (21.6%) were LTF at 1 year after starting ART. The following routinely collected data were used as predictors in two logistic regression models (one to predict death and another to predict LTF): age, gender, weight, CD4 count, WHO Stage, and diagnosis of tuberculosis (TB). The validation cohort consisted of 1,835 adults initiating ART at a different HIV clinic in Haiti during 2012. We assessed model discrimination by measuring the C-statistic, and measured model calibration by how closely the predicted probabilities approximated actual probabilities of the two outcomes. We derived a nomogram and a point-based risk score from the predictive models.

findingsThe model predicting death within the year after starting ART had a C-statistic of 0.75 (95% CI 0.74 to 0.81). There was no evidence for significant overfitting and the predictions were well calibrated. The strongest predictors of 1-year mortality were male gender, low weight, low CD4 count, advanced WHO stage, and the absence of TB. In the validation cohort, the C-statistic was 0.69 (95% CI 0.59 to 0.77). A point-based risk score for death had a C-statistic 0.73 (95% CI 0.69 to 0.76) and categorizes patients as low risk (<2% risk of death), average risk (3-4%), and high-risk (8-10%) and very high-risk (14-19%) with likelihood ratios to be used in settings where the baseline risk is different from our study population. The model predicting LTF did not discriminate well (C-statistic 0.59).

conclusionsA simple risk-score using routinely collected data can predict 1-year mortality after ART initiation for HIV-positive adults in Haiti. However, predicting lost to follow-up using routinely collected data was not as successful. The next step is to assess whether use of this risk score can identify patients who need tailored services to reduce mortality in resource-poor settings such as Haiti.

Indexed as

Developing CountriesAdolescentAdultAgedAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveDrug UtilizationFemaleHaitiHIV InfectionsHumansMaleMiddle AgedAnti-HIV Agents

Identifiers

PMID30157197
PMCPMC6114504
OpenAlexW2889108541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.